Edwards Lifesciences Corporation · NYSE:EW

Edwards Lifesciences — Shareholder Meeting (March 2026)

13 slides from Edwards Lifesciences's shareholder meeting presentation, Mar 26, 2026

  1. Slide 1: Schedule 14A Proxy Statement cover page

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy

  2. Slide 2: Edwards Lifesciences Spring 2026 Stockholder Presentation

    Edwards Lifesciences Spring 2026 Stockholder Presentation

  3. Slide 3: Cautionary Statement and Use of Non-GAAP Financial Measures

    Cautionary Statement and Use of Non-GAAP Financial Measures 2  This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking stateme

  4. Slide 4: We Request Your Support at the 2026 Annual Meeting of Stockholders

    We Request Your Support at the 2026 Annual Meeting of Stockholders 3 Proposal 1. FOR Election of Nine Director Nominees Proposal 2. FOR Advisory Vote to Approve Named Executive Officer Compensation Proposal 3. FOR Ratification of Appointment of Independent Registered Public Accounting Firm Proposal

  5. Slide 5: Our Credo

    At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease. Through our actions, we will become trusted partners with customers, colleagues, and patients – creating a community unified in its mission to improve the quality of life around th

  6. Slide 6: Delivering Sustainable, Differentiated Growth and Leadership with a Unique and Patient-focused Strategy

    5 Focusing on structural heart disease Solving large and complex patient needs Pioneering therapeutic categories Delivering Sustainable, Differentiated Growth and Leadership with a Unique and Patient-focused Strategy

  7. Slide 7: Resulting in Differentiated and Expanded Breakthrough Therapies

    6 Aortic Regurgitation Emerging opportunities Tricuspid Regurgitation Aortic Stenosis Mitral Regurgitation Core innovations SAPIEN KONECTINSPIRIS PASCAL SAPIEN M3 MITRIS SOJOURN Pulmonic Disease ALTERRA CORDELLA EVOQUEPASCAL Structural Heart Failure V-LAP + + TRIFORMIS Resulting in Differentiated an

  8. Slide 8: Innovation brings clinical and economic value to the healthcare ecosystem

    7 Innovation brings clinical and economic value to the healthcare ecosystem to fund innovation globally 1,600+ engineers I N N O V A T I O N S C A L E 100+ countries Leading with innovationLeading with strength, scale and reach Every Heartbeat Matters leading global health access for 2 million more

  9. Slide 9: Well-Qualified Director Nominees with Broad Expertise

    Well-Qualified Director Nominees with Broad Expertise 8 Provides valuable insights and direction to our Board gained through extensive executive management experience at medical technology companies Brings global manufacturing and operational experience in highly regulated industries and experience

  10. Slide 10: Board Skills Tied to Innovation Strategy

    Board Skills Tied to Innovation Strategy 9 Medical Technology Industry Experience International Executive Experience Corporate Governance Risk Oversight and Management Corporate Strategy and Development Executive Leadership Innovation and Research and Development Corporate Impact and Corporate Respo

  11. Slide 11: CEO Pay Element Components and Corporate Performance Measures

    18% 15% 33% 17% 17% CEO Pay Element Components Corporate Performance Measures & Rationale Base Salary Cash  Attract and retain executives Annual Cash Incentive(1) Financial Measurement  Based on underlying revenue growth (60%) and adjusted earnings per share (40%) targets set at the beginning of t

  12. Slide 12: Commitment to Stockholder Engagement

    11 Commitment to Stockholder Engagement We have consistently contacted stockholders holding >50% of outstanding stock each year since 2015 to discuss topics of interest with active participation from an independent director 20 26 20 15 DISCUSSION TOPICS Governance features and stockholder rights Boa

  13. Slide 13: Slide 13

Edwards Lifesciences — Shareholder Meeting (March 2026) on 6ix